Medical research is accelerating thanks to AI-assisted drug discovery, large-scale genomics, and improved clinical trial designs. This hub covers journal breakthroughs, FDA approvals, cancer research, longevity science, and the pipeline of new treatments.
ScienceGuide
Synthetic biology treats DNA as something you write, not just something you edit. How the design–build–test cycle works, the cell built with only 473 genes, what the field has actually delivered — and the 149 genes nobody can explain.
ScienceGuide
An mRNA vaccine doesn't deliver a drug — it delivers instructions your own cells read once and throw away. Here's what really happens, and why the same trick now targets cancer.
HealthGuide
What the research actually shows about screen time and child brain development: the Singapore study linking infant screen use to teen anxiety, the correlation-vs-causation caveat, and the AAP's 2026 shift away from hour limits.
ScienceGuide
CRISPR lets scientists rewrite DNA with startling precision — and it's already curing a genetic disease. Here's how gene editing works, in plain English.
On average, bringing a new drug from discovery to market approval takes 10–15 years and costs more than $1 billion, though AI and platform technologies are compressing timelines.
Clinical trials run in phases: Phase 1 tests safety in a small group, Phase 2 tests effectiveness and side effects, and Phase 3 confirms benefits in large groups before approval. Phase 4 monitors a treatment after it reaches the market.
Gene therapy treats disease by altering a patient's genes — replacing a faulty gene, switching one off, or adding a new one. Recent CRISPR-based therapies, such as the first approved treatment for sickle cell disease, are a landmark example.